NNVC Nanoviricides
- 1.490
- +0.040+2.76%
- 1.529
- +0.039+2.62%
Nanoviricides News
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
NanoViricides CEO Highlights Urgency of H5N1 Preparedness as Cases Rise in North America | NYSE-A:NNVC
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
US pharmaceutical stocks plummet, has the market overreacted to Little Kennedy?
Source: Analysis from Wall Street News states that even if Kennedy is confirmed as the Secretary of Health in the usa, he may not be able to "make a big impact". First, there may be divisions within Trump's team; secondly, it is uncertain whether Kennedy has the authority to appoint leaders of departments like the FDA; finally, Trump may appoint individuals with industry backgrounds as FDA commissioners, directing Kennedy's attention to focus on nutrition rather than pharmaceutical approvals. The famous "anti-vaccine pioneer" and advocate for healthy eating, the new government-nominated Secretary of Health Robert Kennedy, is dining with the loyal "fast food enthusiast" Trump, who promotes rapid vaccine development.
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
NanoViricides: Fiscal Q1 Earnings Snapshot
Nanoviricides | 10-Q: Q1 2025 Earnings Report
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy
Nanoviricides | 10-K: FY2024 Annual Report
NanoViricides Secures First Rights To TheraCour's Antiviral Developments, Eyes Phase II Trials For Lead Drug
Express News | NanoViricides: Obtained Right of First Refusal for All Antiviral Drug Developments From R&D Firm Theracour Pharma
NanoViricides Considers NV-387 for MPOX Treatment Under WHO Protocol Amid Global Outbreak
Express News | NanoViricides: Investigating Possibility of Using NV-387 for Treatment of Mpox Patients Under Who Meuri Protocol
NanoViricides Exploring Emergency Protocol to Evaluate NV-387 for MPOX | NYSE-A:NNVC
Express News | NanoViricides: Anil Diwan Visiting Professionals for Developing Phase II Clinical Trial Plan & Clinical Protocol for Phase II Clinical Trial of NV-387
Express News | NanoViricides: Plans on Exploring Effectiveness of NV-387 for Treatment of Severe Acute Respiratory Infections Caused by Viruses
NanoViricides' NV-387 Aims to Tackle RSV, COVID, and Flu in Upcoming Clinical Trials
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
No Data